-
Hospitals are not the "safe havens" they once were. That is the cautionary message of a recent Sentinel Event Alert by the Joint Commission accrediting body, which focuses on attacks on patients.
-
In a Sentinel Event Alert, The Joint Commission offered the following recommendations for reducing the risk of violence in hospitals:
-
Social networking sites such as Facebook and MySpace continue to be a tricky problem for health care risk managers, who need to ensure that employees do not violate patient privacy even when off duty but also must avoid violating the personal rights of those employees. Failing to address the situation adequately could mean a HIPAA violation or damage to the provider's reputation, but using too heavy a hand could run afoul of labor laws.
-
-
The ECG shown above was obtained from a 50-year-old woman with "skipped beats." Is there anything unusual about these ectopic beats and the effect that they have on the normal beats in this tracing? What happens at the onset of the last lead change (i.e., at the onset where we see leads V4,V5,V6)?
-
More than three-fourths of men have some degree of male pattern hair loss by age 70. The unwanted hair loss seen in male pattern hair loss is stimulated by dihydrotestosterone.
-
Replacing saturated fatty acids with carbohydrates with low glycemic index values is associated with a lower risk of myocardial infarction.
-
In a sample of patients from primary care practice, a single screening question accurately identified drug use.
-
Lorcaserin submitted for FDA review, FDA advisory panel votes against phentermine/topiramate, mixed vote on rosiglitazone, advisory panel votes to remove breast cancer indication from bevacizumab labeling, no increase in seizures found with DTaP vaccine, new REMS for quinine.
-
A new three-drug antihypertensive pill, combining an angiotensin II receptor antagonist (olmesartan [OLM]), a calcium channel blocker (amlodipine [AML]), and a thiazide diuretic (hydrochlorothiazide [HCTZ]), has been approved by the FDA. The new combination is marketed by Daiichi Sankyo as Tribenzor.